hF11
Nomenclature
C57BL/6JSmo-F11tm1(hF11)Smoc
Cat. NO.
NM-HU-210015
Strain State
Repository Live
Gene Summary
Gene Symbol
F11
Model Description
Validation Data
Fig1. Detection of F11 expression in liver by RT-PCR.
Wild type: only one band at 364 bp with primers F1/R1(mF11);
Homozygous: only one band at 364 bp with primers F2/R2(hF11);
Abbr. M, DNA marker; HO, homozygous; WT, wild type.
Fig 2. Detection of hF11 expression in plasma by ELISA (female，RayBiotech, ELH-CoagFXI-1).
Abbr. HO, homozygous; WT, wild type.
Fig3. Detection of hF11 expression in plasma by ELISA (male，Abcam, ab108834).
Abbr. HO, homozygous; WT, wild type.
Fig4. Prothrombinogen time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB) in hF11 mice. （male, A. 8-10 weeks of age; B. 10-12 weeks of age.)
Fig.5 Activated Partial Thromboplastin Time (APTT) of anti-human F11 antibody in hF11 mice. Compared with the PBS control group, Abelacimab treatment significantly prolonged APTT. At day 7 post-treatment, the degree of APTT prolongation was significantly greater in the high-dose group compared to the low-dose group. The hF11 mice were randomly divided into 3 groups (n=5 per group, 9 weeks old, male). Anti-human F11 antibody Abelacimab or PBS was administered via intravenous injection. Plasma samples for coagulation assessment were collected at pre-treatment (baseline), day 1, and day 7 following treatment. APTT was measured using citrated plasma samples according to standard protocol.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
